Literature DB >> 12176103

In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation.

Roland Baron1, Yannis Tsouderos.   

Abstract

In order to determine whether 5-[bis(carboxymethyl) amino]-2-carboxy4-cyano-3-thiopheneacetic acid distrontium salt (S12911-2) inhibits bone resorption by acting on the differentiation and/or function of osteoclasts, its effects were assessed on the 1,25-dihydroxyvitamin D(3)-induced expression of carbonic anhydrase II and vitronectin receptor in chicken bone marrow cells, and on the resorbing activity of authentic rat osteoclasts cultured on bone slices. S12911-2 dose-dependently inhibited, after a 6-day exposure, the expression of carbonic anhydrase II and vitronectin receptor in stimulated osteoclasts (46% and 40%, respectively, at 10(-3) M Sr(2+), P<0.05). A pre-incubation of bone slices with S12911-2 induced a dose-dependent inhibition of bone resorbing activity from 32% at 10(-4) M Sr(2+) to 66% at 10(-3) M Sr(2+) (P<0.05 in each case). A continuous incubation (10(-3) M Sr(2+)) induced a greater inhibition of bone resorbing activity (73%, P<0.05). The inhibition of bone resorption obtained specifically with S12911-2 is related to an inhibition of the differentiation and resorbing activity of the osteoclasts.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12176103     DOI: 10.1016/s0014-2999(02)02040-x

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  51 in total

1.  Serum osteoprotegerin concentration with strontium ranelate treatment for postmenopausal osteoporosis: an open, prospective study.

Authors:  Melek Eda Ertorer; Okan Bakiner; Inan Anaforoglu; Nurzen Sezgin; Nilgun Guvener Demirag; Neslihan Bascil Tutuncu
Journal:  Curr Ther Res Clin Exp       Date:  2007-07

2.  Strontium Ranelate: Long-Term Efficacy against Vertebral, Nonvertebral and Hip Fractures in Patients with Postmenopausal Osteoporosis.

Authors:  Jean-Yves Reginster; Mickaël Hiligsmann; Olivier Bruyere
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-06       Impact factor: 5.346

Review 3.  Targeting subchondral bone for treating osteoarthritis: what is the evidence?

Authors:  Steeve Kwan Tat; Daniel Lajeunesse; Jean-Pierre Pelletier; Johanne Martel-Pelletier
Journal:  Best Pract Res Clin Rheumatol       Date:  2010-02       Impact factor: 4.098

Review 4.  Strontium ranelate: a novel mode of action leading to renewed bone quality.

Authors:  Patrick Ammann
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

Review 5.  Strontium ranelate: a novel mode of action optimizing bone formation and resorption.

Authors:  P J Marie
Journal:  Osteoporos Int       Date:  2005-01       Impact factor: 4.507

6.  Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies.

Authors:  J Y Reginster; P J Meunier
Journal:  Osteoporos Int       Date:  2003-03-12       Impact factor: 4.507

Review 7.  Optimizing bone metabolism in osteoporosis: insight into the pharmacologic profile of strontium ranelate.

Authors:  P J Marie
Journal:  Osteoporos Int       Date:  2003-03-18       Impact factor: 4.507

8.  Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats.

Authors:  Y F Li; E Luo; G Feng; S S Zhu; J H Li; J Hu
Journal:  Osteoporos Int       Date:  2009-12-03       Impact factor: 4.507

9.  Positive impact of compliance to strontium ranelate on the risk of nonvertebral osteoporotic fractures.

Authors:  V Rabenda; J-Y Reginster
Journal:  Osteoporos Int       Date:  2010-01-16       Impact factor: 4.507

Review 10.  The osteoporotic male: overlooked and undermanaged?

Authors:  Bruno Madeo; Lucia Zirilli; Giovanni Caffagni; Chiara Diazzi; Alessia Sanguanini; Elisa Pignatti; Cesare Carani; Vincenzo Rochira
Journal:  Clin Interv Aging       Date:  2007       Impact factor: 4.458

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.